EVMN: Evommune, Inc.
Performance
EVMN -58.45%
Watchlist
Select an item
Summary
EVMN at a glance
EVMN returned -58.45% over the past year. Its worst drop in that year was -83.85%, smaller than 1% of stocks on Redstone, and its Sharpe ratio of -0.21 beats 19% of stocks on Redstone. It pays no dividends.
Current Drawdown
-75.77%
Rolling Volatility
117.26%
Actions
Metrics
Risk Indicators
Alpha-34.77%
Beta1.03x
Sharpe-0.21
Sortino-0.33
Omega0.96
Calmar-0.70
Martin-0.55
Profile
About EVMN
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC).
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $278M
- Listed
- Nov 2025
- Employees
- 48
- Headquarters
- Palo Alto, CA
- Website
- evommune.com
Comparisons